Finally, we tested the hypothesis whether canine histiocytic sarcoma (HS), a malignant canine tumor of interstitial DC origin that does not undergo regression but usually progresses with poor prognosis, lacks CD80 and CD86 expression. This evidence concerns the gene CD80 and histiocytic sarcoma.